We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+13.25%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$1.05B
AUM Growth
+$53.4M
Cap. Flow
-$44.1M
Cap. Flow %
-4.2%
Top 10 Hldgs %
70.43%
Holding
48
New
17
Increased
6
Reduced
6
Closed
15
Avg Time Held Equity + Options
2.5 quarters
Top 10 Avg Time Held Equity + Options
4.2 quarters
Top 20 Avg Time Held Equity + Options
2.9 quarters
Avg Time Held Equity only
2.8 quarters
Top 10 Avg Time Held Equity only
4.3 quarters
Top 20 Avg Time Held Equity only
2.9 quarters

Top Buys

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$50.1M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$35M
3
SGMO icon
SANGAMO THERAPEUTICS INC
SGMO
+$25.1M
4
UBX icon
Unity Biotechnology
UBX
+$24.6M
5
KZR icon
Kezar Life Sciences
KZR
+$22.2M

Top Sells

Rank Stock Value
1
ARRY icon
Array Biopharma Inc
ARRY
+$49.8M
2
WVE icon
Wave Life Sciences
WVE
+$45M
3
ASND icon
Ascendis Pharma A/S
ASND
+$23.6M
4
APLS icon
Apellis Pharmaceuticals
APLS
+$23.4M
5
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$22.7M

Sector Composition

Rank Sector Weight
1 Healthcare 87.08%
2 Miscellaneous 12.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ASMB icon
26
CALL
Assembly Biosciences
ASMB
$417M
$5.81M 0.55%
+12,342
New +$6.53M
2018 Q2
0 quarters
DBVT icon
27
DBV Technologies S.A. American Depositary Shares
DBVT
$569M
$5.75M 0.55%
29,810
-15,190
-34% -$3.42M
2018 Q1
1 quarter
CRVS icon
28
Corvus Pharmaceuticals
CRVS
$788M
$4.95M 0.47%
450,400
-19,300
-4% -$215K
2017 Q2
4 quarters
NGNE icon
29
Neurogene
NGNE
$440M
$3.05M 0.29%
+57,500
New +$15M
2018 Q2
0 quarters
TRAW icon
30
Traws Pharma
TRAW
$6.3M
$3.03M 0.29%
+1,333
New +$3.87M
2018 Q2
0 quarters
PHXM
31
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$1.73M 0.17%
+15,396
New +$2.89M
2018 Q2
0 quarters
APTX
32
DELISTED
Aptinyx Inc. Common Stock
APTX
$992K 0.09%
+41,037
New +$878K
2018 Q2
0 quarters
INFI
33
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$787K 0.07%
+412,000
New +$832K
2018 Q2
0 quarters
AGIO icon
34
Agios Pharmaceuticals
AGIO
$1.81B
– –
-172,952
Closed -$14.1M –
AKBA icon
35
Akebia Therapeutics
AKBA
$208M
– –
-1,425,000
Closed -$13.6M –
APLS icon
36
DELISTED
Apellis Pharmaceuticals
APLS
– –
-1,056,348
Closed -$23.4M –
DNLI icon
37
Denali Therapeutics
DNLI
$2.9B
– –
-325,000
Closed -$6.4M –
GERN icon
38
Geron
GERN
$758M
– –
-350,000
Closed -$1.49M –
PTGX icon
39
Protagonist Therapeutics
PTGX
$9.05B
– –
-1,083,567
Closed -$9.31M –
RYTM icon
40
Rhythm Pharmaceuticals
RYTM
$6B
– –
-318,564
Closed -$6.34M –
SYBX icon
41
DELISTED
Synlogic
SYBX
– –
-46,667
Closed -$6.57M –
URGN icon
42
UroGen Pharma
URGN
$1.87B
– –
-402,300
Closed -$20M –
ATYR icon
43
aTyr Pharma
ATYR
$19.9M
– –
-279,855
Closed -$10.6M –
LUMO icon
44
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-62,222
Closed -$4.06M –
KIN
45
DELISTED
Kindred Biosciences, Inc.
KIN
– –
-248,680
Closed -$2.15M –
FPRX
46
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-1,240,470
Closed -$21.3M –
DOVA
47
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
– –
-429,729
Closed -$11.7M –
ARRY icon
48
DELISTED
Array Biopharma Inc
ARRY
– –
-3,049,312
Closed -$49.8M –
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2018 Portfolio in Review

As of Q2 2018, EcoR1 Capital held 48 positions worth $1.05B, up 5.4% from $997M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

EcoR1 Capital withdrew a net $44.1M in Q2 2018, closing 15 positions and reducing 6 holdings. Its most notable exit was Array Biopharma Inc, an estimated $49.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 94% a quarter earlier, followed by Miscellaneous.

Against the trend, EcoR1 Capital opened a new position in Scholar Rock worth $41.7M.

  • EcoR1 Capital's largest Q2 2018 buy was Scholar Rock: 2,671,161 shares worth $41.7M.
  • EcoR1 Capital added most to Ironwood Pharmaceuticals in Q2 2018, an estimated $6.44M increase.
  • EcoR1 Capital's biggest Q2 2018 reduction was Wave Life Sciences, cutting an estimated $45M.
  • EcoR1 Capital fully exited Array Biopharma Inc in Q2 2018, selling an estimated $49.8M.
  • EcoR1 Capital's ten largest holdings make up 70% of its $1.05B portfolio in Q2 2018.
  • EcoR1 Capital opened 17 new positions and closed 15 in Q2 2018.
  • EcoR1 Capital's portfolio value rose 5.4% quarter-over-quarter to $1.05B.

Based on EcoR1 Capital's 13F filing for Q2 2018, filed 14 Aug 2018.